NNC9204-1706

NNC9204-1706 or NN9423 is a GLP-1/GIP/glucagon receptor triple agonist developed by Novo Nordisk.[1][2] It was evaluated in a clinical trial;[3][4] adverse effects such as "dose-dependent increases in heart rate and reductions in reticulocyte count, increases in markers of inflammation and hepatic disturbances, and impaired glucose tolerance at the highest dosages" meant that the drug was declared to have an inadequate safety profile and discontinued.[5]

References

  1. ^ Jepsen, Mathies M.; Christensen, Mikkel B. (September 2021). "Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity". Expert Opinion on Emerging Drugs. 26 (3): 231–243. doi:10.1080/14728214.2021.1947240. ISSN 1744-7623. PMID 34176426. S2CID 235661514.
  2. ^ Bergmann, Natasha Chidekel; Davies, Melanie J.; Lingvay, Ildiko; Knop, Filip K. (January 2023). "Semaglutide for the treatment of overweight and obesity: A review". Diabetes, Obesity and Metabolism. 25 (1): 18–35. doi:10.1111/dom.14863. ISSN 1462-8902. PMC 10092086. PMID 36254579.
  3. ^ Abdi Beshir, Semira; Ahmed Elnour, Asim; Soorya, Aadith; Parveen Mohamed, Affana; Sir Loon Goh, Sheron; Hussain, Nadia; Al Haddad, Amal H. I.; Hussain, Faizah; Yousif Khidir, Israa; Abdelnassir, Zainab (1 October 2023). "A narrative review of approved and emerging anti-obesity medications". Saudi Pharmaceutical Journal. 31 (10): 101757. doi:10.1016/j.jsps.2023.101757. ISSN 1319-0164. PMC 10497995. PMID 37712012.
  4. ^ Müller, Timo D.; Blüher, Matthias; Tschöp, Matthias H.; DiMarchi, Richard D. (2022). "Anti-obesity drug discovery: advances and challenges". Nature Reviews. Drug Discovery. 21 (3): 201–223. doi:10.1038/s41573-021-00337-8. ISSN 1474-1776. PMC 8609996. PMID 34815532.
  5. ^ Novikoff, Aaron; Müller, Timo D. (2023). "The molecular pharmacology of glucagon agonists in diabetes and obesity". Peptides. 165: 171003. doi:10.1016/j.peptides.2023.171003. ISSN 0196-9781. PMC 10265134. PMID 36997003.